Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 28, 2021 - Issue 3
Submit an article Journal homepage
2,643
Views
8
CrossRef citations to date
0
Altmetric
Articles

A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis

Thibaud Damya Department of Cardiology, Referral Center for Cardiac Amyloidosis, GRC Amyloid Research Institute, DHU A-TVB, APHP CHU Henri Mondor and Université Paris Est Créteil, Créteil, FranceORCID Iconhttps://orcid.org/0000-0003-4058-3848View further author information
ORCID Icon,
Isabel Conceiçãob Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal;c Department of Neurosciences and Mental Health, CHULN-Hospital de Santa Maria, CHULN, Hospital de Santa Maria, Lisboa, PortugalView further author information
,
Pablo García-Pavíad Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, CIBERCV, Madrid, Spain;e Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, SpainView further author information
,
Julian Gillmoref Division of Medicine, National Amyloidosis Centre, University College London, London, UKORCID Iconhttps://orcid.org/0000-0001-6174-9232View further author information
ORCID Icon,
Ravi Jandhyalag Medialis Ltd., Banbury, UK;h Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, Faculty of Life Science & Medicine, King’s College University, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7241-7476View further author information
ORCID Icon,
Jan Sabbati Akcea Therapeutics UK, Surrey, UKView further author information
,
Jonas Wixnerj Department of Public Health and Clinical Medicine, Umeå University, Umeå, SwedenView further author information
&
Teresa Coelhok Andrade’s Center for Familial Amyloidosis, Porto, Portugal;l Department of Neurosciences, Hospital de Santo António, Porto, PortugalView further author information
 show all
Pages 189-198 | Received 05 Jan 2021, Accepted 13 May 2021, Published online: 27 May 2021

References

  • Reddy S, Chang E, Tarbox M, et al. The clinical and economic burden of newly diagnosed hereditary transthyretin (ATTRv) amyloidosis: a retrospective analysis of claims data. Neurol Ther. 2020;9(2):473–482.
  • Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281(4):337–347.
  • Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. 2019;29(2):245–251.
  • Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):1–18.
  • Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404.
  • Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109.
  • Koike H, Fukami Y, Nishi R, et al. Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis. Neurol Clin Neurosci. 2019;7(4):166–173.
  • Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50–57.
  • Moshe-Lilie O, Dimitrova D, Heitner SB, et al. TTR knockdown therapy in patients with hATTR amyloidosis who have disease progression despite liver transplant. Neurology. 2019;92(15 Suppl):P5.4–013.
  • Trotter JP. Patient registries: a new gold standard for “real world” research. Ochsner J. 2002;4(4):211–214.
  • von Martial S, Brix TJ, Klotz L, et al. EMR-integrated minimal core dataset for routine health care and multiple research settings: a case study for neuroinflammatory demyelinating diseases. PLoS One. 2019;14(10):e0223886.
  • Daniel BS, Hertl M, Werth VP, et al. Severity score indexes for blistering diseases. Clin Dermatol. 2012;30(1):108–113.
  • McKee AE, Farrell AT, Pazdur R, et al. The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(S1):13–18.
  • Jandhyala R. A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Curr Med Res. 2020;36(5):883–893.
  • Jandhyala R. Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res. 2020;36(11):1873–1887.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.